

Announcement Summary

Entity name

BCAL DIAGNOSTICS LIMITED

Announcement Type

New announcement

Date of this announcement

Monday September 18, 2023

The +securities to be quoted are:

Other

Total number of +securities to be quoted

ASX +security code	Security description	Number of +securities to be quoted	Issue date
BDX	ORDINARY FULLY PAID	200,000	18/09/2023

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

BCAL DIAGNOSTICS LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2 Registered number type

Registration number

ABN

51142051223

1.3 ASX issuer code

BDX

1.4 The announcement is

☑ New announcement

1.5 Date of this announcement

18/9/2023



Part 2 - Type of Issue

2.1 The +securities to be quoted are:

Other

2.2 The +securities to be quoted are:

☑ Additional +securities in a class that is already quoted on ASX ("existing class")

2.3c Have these +securities been offered under a +disclosure document or +PDS? $\ensuremath{\mathfrak{C}}$ No

2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

Issue to CEO, resident in US ineligible to participate in SPP.

https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02712947-2A1474466?access_token=8 3ff96335c2d45a094df02a206a39ff4

2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

☑ The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities to be quoted in an existing class

ASX +security code and description

BDX: ORDINARY FULLY PAID

Issue date

18/9/2023

Issue details

Number of +securities to be quoted

200,000

Are the +securities being issued for a cash consideration?

Yes

In what currency is the cash consideration being paid? What is the issue price per +security?

AUD - Australian Dollar AUD 0.10000000

Any other information the entity wishes to provide about the +securities to be quoted

https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02712947-2A1474466?access_token=8 3ff96335c2d45a094df02a206a39ff4

The purpose(s) for which the entity is issuing the securities

To raise additional working capital



Part 4 - Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)

ASX +security code and description

Total number of +securities on issue

BDX: ORDINARY FULLY PAID 236,932,693

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
BDXAF : PERFORMANCE RIGHTS	8,294,022
BDXAC : OPTION EXPIRING 23-NOV-2023 EX \$0.0574	5,778,965
BDXAD : OPTION EXPIRING 20-NOV-2029 EX \$0.0574	3,467,353



Part 5 - Other Listing Rule requirements

- 5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1? ☑ No
- 5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

☑ No

- 5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?
 ☑ Yes
- 5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

200,000

5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?
⊗ N/A